MYE FORMS REVEALED RESPONSE CODES OBJECTIVES. Stringent Complete Response (scr) Complete Response (CR) I have no conflicts of interest to disclose
|
|
- Cornelius Harrell
- 6 years ago
- Views:
Transcription
1 I have no conflicts of interest to disclose MYE FORMS REVEALED Janet Brunner, PA-C CIBMTR MKE New10_1.ppt OBJECTIVES 1) Be able to describe the criteria required for each myeloma response code 2) Be able to identify the appropriate baseline studies to use when determining response to therapy for myeloma patients 3) Be able to report the proper response code when two consecutive assessments have not been obtained during the same reporting period RESPONSE CODES New10_2.ppt Complete Response (CR) Negative immunofixation on serum and urine samples (this is required) Disappearance of any soft tissue plasmacytomas and <5% plasma cells in the bone marrow (confirmation with repeat marrow biopsy not needed) Stringent Complete Response (scr) Negative immunofixation on serum and urine samples (this is required) Disappearance of any soft tissue plasmacytomas and <5% plasma cells in the bone marrow (confirmation with repeat marrow biopsy not needed) PLUS.. 1
2 Normal free light chain ratio, and Absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence Very Good Partial Response (VGPR) Serum & urine M-protein detectable by immunofixation, but not on electrophoresis (i.e. SPEP or UPEP) or >90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours Partial Response (PR) >50% reduction in serum M-protein and Reduction in 24-hour urinary M-protein by >90% or to <200 mg/24 hours Stable Disease (SD) Not meeting the criteria for CR, VGPR, PR or PD Progressive Disease (PD) Requires one or more of the following: Increase of >25% from baseline in serum M- protein and/or an absolute increase >0.5 g/dl Increase of >25% from baseline in urine M- protein and/or an absolute increase >200 mg/24 hours For recipients without measurable serum & urine M-protein levels: an absolute increase of >10 mg/dl in the difference between involved & uninvolved free light chain levels Relapse from CR (Rel) Requires one or more of the following: Reappearance of serum or urine M- protein by immunofixation or electrophoresis Development of >5% plasma cells in the bone marrow Appearance of any other sign of progression (e.g. new plasmacytomas, lytic bone lesion, hypercalcemia) 2
3 Definition of Measurable Disease Measurable disease is defined by at least one of the following three measurements: Serum M-protein >/= 1 gram/dl (based on SPEP and not SIFE) Urine M-protein >/=200 mg/24 hrs Serum FLC assay: Involved FLC level >/=10 mg/dl provided the serum FLC ratio is abnormal Measurable vs. non-measurable disease is determined at diagnosis What happens when you have a patient without measurable disease? When trying to determine a PR, a >50% reduction in plasma cells is required in place of the M-protein, provided the baseline bone marrow plasma cells was >30% In addition, a >50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. Reporting a Response Code Reporting a response code (scr, CR, VGPR, PR, SD or PD) requires two consecutive assessments made at any time before the institution of any new therapy & no evidence of progression or new bone lesions if radiographic studies were performed; Note- radiographic studies are not required to satisfy scr, CR, VGPR, PR, SD or PD requirements. continued Relapse requires two consecutive assessments made at any time before classification as relapse, and/or the institution of any new therapy What is the proper response code to report when two consecutive assessments have not been obtained in the same reporting period? Keep in mind the six week interval between consecutive assessments is no longer required 3
4 Example A 60 year old WM receives an Auto PBSC HSCT for Multiple Myeloma. At Day +100, it is determined that he has achieved a VGPR in response to the HSCT. He s monitored on a monthly basis & on the last set of labs obtained at the time of his 6 month f/u visit he now meets the criteria for CR. He s doing well and does not return for f/u until 3 months later. Labs at that time confirm that he is in CR. He remains in CR for 2 more years. What is the proper response code to report at 6 months? A) Very Good Partial Remission (VGPR) B) Partial Remission (PR) C) Complete Remission (CR) D)Stable Disease (SD) Survey says (A) When there hasn t been a second assessment in the same reporting period to confirm the response, you report the disease status that was previously confirmed. In this example, you would report VGPR at 6 months. At 1 year, you would report the CR & the date when the CR was first documented. In other words, even though documentation of response requires a confirmatory measurement, the start time for date of response is the first date at which the response was noted. Case #1 Case Studies Patient received planned maintenance therapy (Revlimid) starting on Day 100. A F2116 (Myeloma Post-HSCT) comes due at 6 months. Q20- Was planned treatment per protocol given since the date of the last report? YES (Revlimid) Q Best response to line of therapy need to be answered. What baseline studies would you use to determine the response he/she may have had to the Revlimid? 4
5 Case #1 A) Use the labs obtained prior to starting Revlimid B) Use the labs obtained at diagnosis C) Use the labs obtained immediately prior to the start of the preparative regimen for HSCT Survey says.. (B) Case #2 A patient is diagnosed with IgG kappa myeloma. M-spike =6000 mg/l (from SPEP) 24-hr urine M-protein = 1000 mg/24 hrs Bone marrow biopsy had 40% plasma cells. Patient was treated with Velcade, Doxil & Dexamethasone for 4 cycles Patient was re-evaluated after the 4 th cycle of VDD. The M-spike = 2400 mg/l & there were 15% plasma cells on the bone marrow biopsy. The patient achieved a PR. The patient received Cytoxan for autologous stem cell mobilization. The next set of labs were obtained immediately prior to the start of the prep regimen. The M-spike = 1600 mg/l & 8% plasma cells were noted on the bone marrow biopsy. What is the patient s disease status immediately prior to the start of the preparative regimen? A) Stable Disease (SD) B) Very Good Partial Remission i (VGPR) C) Partial Remission (PR) D)I don t know- not enough information provided to make determination Survey says.. (C) Case #3 The recipient from case #2 has had their autologous HSCT. Lab studies are obtained at 60 & 100 days post HSCT. SPEP/UPEP are negative for an M-spike at Day 60 & 100 Serum & Urine Immunofixation are positive for IgG kappa at Day 60 & 100 Bone marrow biopsy <5% plasma cells at Day 100 Case #3 What disease response code would you report for this recipient at 100 days post-hsct? A) Partial Remission (PR) B) Very Good Partial Remission i (VGPR) C) Complete Remission (CR) D) None of the above Survey says.. (B) 5
6 A 55 year old AA male is diagnosed with IgG lambda myeloma. Results of the initial work-up include- Serum M-spike = 4000 mg/l 24-hr urine M-protein = 1000 mg/24 hr Bone marrow biopsy = 60% plasma cells Patient receives 2 cycles of Revlimid & Dexamethasone & then re-evaluated Serum M-spike = 2000 mg/l 24-hr urine M-protein = 190 mg/24 hr What is the patient s disease response after two cycles of Rev/Dex? A) Partial Remission (PR) B) Very Good Partial Remission (VGPR) C) Stable Disease (SD) Survey says (A) The patient s PR status was confirmed with a 2 nd measurement. The patient received two additional cycles of Rev/Dex & then re-evaluated for disease response. Serum M-spike = 2900 mg/l 24-hr urine M-protein = 600 mg/24 hr Bone marrow biopsy = 30% plasma cells What is the patient s disease response after a total of 4 cycles of Rev/Dex? A) Stable Disease (SD) B) Progressive Disease (PD) C) Partial Remission (PR) Survey says (B) Patient is switched to Vincristine, Adriamycin & Decadron (VAD) and is reevaluated after two cycles. Serum M-spike = 1400 mg/l 24-hr urine M-protein = 190 mg/24 hr Bone marrow biopsy = 15% plasma cells The plan is to give IV Cytoxan mobilization. What is the patient s disease response to the 2 cycles of VAD? The patient has achieved a PR after two cycles of VAD. What studies were used as a baseline to make that determination? A) The studies obtained at diagnosis B) The studies obtained at time of progression C) The studies obtained after first two cycles of Rev/Dex Survey says (B) 6
7 The patient has undergone their autologous PBSC HSCT & has been evaluated monthly for the 1 st three months post HSCT. Day +30 evaluation: Serum M-spike = 1000 mg/l Serum immunofixation (+) for IgG lambda 24-hr urine M-protein = 190 mg/24 hrs Bone marrow biopsy = 7% plasma cells Day +60 evaluation: SPEP/UPEP- no monoclonal band Serum/Urine immunofixation (+) for IgG lambda 24-hr urine for M-protein = 90 mg/24 hrs Day +100 evaluation: SPEP/UPEP- no monoclonal band Serum/Urine immunofixation (+) for IgG lambda 24-hr urine for M-protein = 90 mg/24 hrs Bone marrow biopsy <5% plasma cells What is the best disease response to HSCT that you would report at Day +100 for this patient? A) Stable Disease (SD) B) Partial Remission i (PR) C) Very Good Partial Remission (VGPR) D)Complete Remission (CR) Survey says.. (C) Insights from Dr. Hari regarding Formal vs. Practical Response Assessments Many centers are not doing 24-hr urine studies on myeloma patients anymore. Disease response criteria for PR requires a >50% reduction in the serum M-protein and a reduction in the 24-hr urine M-protein by >90% or to <200 mg/24 hrs. How should data managers handle these types of situations? Dr Hari s response.. If the patient s main paraprotein is in the serum, then I tell them to go ahead and use the serum alone for PR vs. no response, etc. If it is CR that we are looking for, then I insist on urine studies. If a 24-hr urine was not done at least a random urine has to be immunofixation (IFE) negative. 7
8 If the patient has light chain only disease & the urine was the major site of disease, one will not be able to assess for a response without urine studies. Currently, the response criteria do not allow serum free light chain studies as a substitute for urine studies. 8
FAQs- Janet s Inbox. Janet Brunner, PA-C Wed. Feb. 26, 2014 TRAINING & DEVELOPMENT 1.
FAQs- Janet s Inbox Janet Brunner, PA-C Wed. Feb. 26, 2014 TRAINING & DEVELOPMENT 1. Disclosures I have no relevant conflicts of interest to disclose. TRAINING & DEVELOPMENT 2. Objectives 1. Determine
More informationTracking Disease Status for Multiple Myeloma
Tracking Disease Status for Multiple Myeloma This appendix is intended to provide additional resources when determining: Best response to line of therapy pre-transplant; Disease Status at the Last Evaluation
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016
MYELOMA Quantitative Markers-Myeloma Assessment Quantitative markers are biochemicals that are recorded in tests on body fluids such as serum and urine. Applicable Disease Sites The myeloma disease site
More informationPlasma Cell Disorders (PCD) Pre-HCT Data
Plasma Cell Disorders (PCD) Pre-HCT Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: HCT type: (check
More information2016: Plasma Cell Disorders Pre-HCT Data
2016: Plasma Cell Disorders Pre-HCT Data Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Date of HCT for which this form is being completed: / / YYYY MM DD HCT type (check
More informationInstructions for Plasma Cell Disorders (PCD) Post-HCT Data (Form 2116 Revision 3)
(Form 2116 Revision 3) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Plasma Cell Disorders (PCD) Post-HCT Data Form. E-mail comments regarding the
More informationCriteria for Disease Assessment Joan Bladé
Criteria for Disease Assessment Joan Bladé Unidad de Amiloidosis y Mieloma Servicio de Hematología Hospital Clínic de Barcelona COMy Meeting, París, May 4th, 2018 Response Evaluation EBMT, 1998 - CR and
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationForms Revision: Myeloma Changes
Sharing knowledge. Sharing hope. Forms Revision: Myeloma Changes J. Brunner, PA-C and A. Dispenzieri, MD February 2013 Disclosures Janet Brunner, PA-C I have no relevant conflicts of interest to disclose.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy
More informationImportancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple
Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple Joan Bladé Unidad de Amiloidosis y Mieloma Servicio de Hematología Hospital Clínic de Barcelona Málaga, 16 de noviembre
More informationI Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015
I Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015 Larry Anderson, MD, PhD Plasma Cell Disorder and Stem Cell Transplant Specialist UT Southwestern Medical
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Frontline Therapy for Newly Diagnosed Patients Saad Usmani, MD FACP Levine Cancer Institute Introduction: Case Presentation 64-year-old woman with
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationMyeloma: Are We on the Brink of a Cure? Jeffrey Wolf, MD Director, Myeloma Program University of California, San Francisco
Myeloma: Are We on the Brink of a Cure? Jeffrey Wolf, MD Director, Myeloma Program University of California, San Francisco Survival in Myeloma IFM DFCI; 2015 2011-14 2001-10 1961-70 1991-2000 Kumar S.
More informationM-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016
+ M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016 + Disclosures Advisory Boards: AMGEN, Lundbeck, NOVARTIS + Subtypes of Plasma Cell Disorders Increased Plasma
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 9: , 2015
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1895-1900, 2015 Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationSmoldering Multiple Myeloma. A Case Study
Smoldering Multiple Myeloma A Case Study Case Presentation 53-Year-Old Male Patient presented for a routine exam No prior history of disease or family history of fhematologic disorders d or malignancies,
More informationTreatment of Relapsed. A Case Study
Treatment of Relapsed Multiple Myeloma A Case Study Case Presentation Mr. V is a 61-year-old man previously diagnosed with ISS stage III IgG λ multiple myeloma with bone lesions, normal FISH and cytogenetics,
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More informationSerum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial
Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial Jill Corre*, Thomas Dejoie, Helene Caillon, Michel Attal*,
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationCitation for published version (APA): Hovenga, S. (2007). Clinical and biological aspects of Multiple Myeloma s.n.
University of Groningen Clinical and biological aspects of Multiple Myeloma Hovenga, Sjoerd IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationMajor Diagnostic Criteria
Multiple Myeloma Elizabeth Ann Coleman, PhD, RNP, AOCN Professor and Chair, Dept. of Nursing Science Cooper Chair in Oncology Nursing, College of Nursing Professor, Dept. of Internal Medicine, College
More informationLaboratory Examination
Todd Zimmerman, M.D. 64 year old African American male presents to establish care with PCG. Meds: Norvasc 5 mg daily PMHx: HTN x 20 years, poorly controlled SHx: No tobacco, illicit; rare EtOH ROS: Negative
More informationSheena Surindran Grand Rounds 2/15/11
Sheena Surindran Grand Rounds 2/15/11 Affects 5 12 person per million / year 5 10% associated with myeloma Median survival without treatment is 12 40 months Most commonly affected organs are kidney, heart
More informationThe Paraprotein. Evaluating Paraproteinemia. Conditions Associated with PP. Paraprotein Structure
Evaluating Paraproteinemia Jeffrey Wolf, MD, Director Thomas Martin, MD, Associate Director Myeloma Institute University of California, San Francisco The Paraprotein An abnormal immunoglobulin or part
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationEvaluating Paraproteinemia
Evaluating Paraproteinemia Jeffrey Wolf, MD, Director Thomas Martin, MD, Associate Director Myeloma Institute University of California, San Francisco The Paraprotein An abnormal immunoglobulin or part
More informationHematology 101. Rachid Baz, M.D. 5/16/2014
Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More
More informationMultiple Myeloma 101: Understanding Your Labs
Multiple Myeloma 101: Understanding Your Labs Tim Wassenaar MD MS Hematologist, Director of Clinical Trials UW Cancer Center at ProHealth Care None Disclosures Outline Define hematopoiesis WBCs, RBCs,
More informationMultiple Myeloma (MM)
EloreMed Editor: Le Wang, MD, PhD Date of Update: 2/14/2018 UpToDate: New FDA approval anti-myeloma drugs: Carfizomid, Ixazomib, Daratumumab, Elotumumab, Pomalidomide. Autologous stem cell transplantation
More informationPLASMA CELL NEOPLASIA. Michael Miller, MD & Ajaz Shawl, MD
PLASMA CELL NEOPLASIA Michael Miller, MD & Ajaz Shawl, MD Plasma Cell Neoplasia Board Questions Case Presentation Introduction Epidemiology Presentation Diagnosis Laboratory Tests Imaging Differentials
More informationReview of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM
Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM Multiple myeloma Response evaluation Kumar Lancet Oncol 2016; 17: e328 46 Cumulative Proportion Surviving
More informationJo Abraham MD Division of Nephrology University of Utah
Jo Abraham MD Division of Nephrology University of Utah 68 year old male presented 3 weeks ago with a 3 month history of increasing fatigue He reported a 1 week history of increasing dyspnea with a productive
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationManagement Update: Multiple Myeloma. Presented by Prof. Dr. Khan Abul Kalam Azad Professor of Medicine Dhaka Medical College
Management Update: Multiple Myeloma Presented by Prof. Dr. Khan Abul Kalam Azad Professor of Medicine Dhaka Medical College Introduction Multiple myeloma - clonal plasma cell neoplasm Monoclonal antibody
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationSuspecting Tumors, or Could it be cancer?
Suspecting Tumors, or Could it be cancer? Donna E. Reece, M.D. Princess Margaret Cancer Centre University Health Network Toronto, ON CANADA 07 February 2018 Background Low back pain is common However,
More informationCancer Research Group Version Date: June 22, 2016 NCI Update Date: November 13, Schema
ev. 5/14 Cancer esearch Group Schema NDUCTON 1, 3 rm Step 0 P E - E G S T T O Step 1 N D O M Z T O Stratification: ntent to stem cell transplant at progression: Yes or No Bortezomib 1.3 mg/m2 SQ or V days
More informationRefractory M ultiple Multiple M yeloma Myeloma
Refractory Multiple Myeloma A Case Study Case: #1 48-Year-Old Male Presented to the ER with Fatigue and Acute Severe Lower Back Pain Patient assessment: X-ray of lumbar spine: L4 compression fracture,
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationInternational Myeloma Foundation Patient and Family Seminar
International Myeloma Foundation Patient and Family Seminar Vienna, Austria May 6 th, 2006 New Development in Diagnosis & Treatments Brian G.M. Durie, M.D., Chairman International Myeloma Foundation What
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
MULTIPLE MYELOMA Updated March 2017 by Doreen Ezeife, PGY-5 resident, University of Calgary Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist,
More informationSerum free light chain (SFLC) assays. Dr Sarah Sasson SydPath Registrar
Serum free light chain (SFLC) assays Dr Sarah Sasson SydPath Registrar Introduction to SFLC Plasma cell dyscrasias such as monoclonal gammopathy of uncertain significance (MGUS) smouldering/asymptomatic
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationCase Study Discussions on the Nurse s Role in Caring for Patients With Hematologic Malignancies
Case Study Discussions on the Nurse s Role in Caring for Patients With Hematologic Malignancies Case Study Discussions on the Nurse s Role in Caring for Patients With Hematologic Malignancies Welcome and
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationAmyloidosis: What to do and how to diagnose: An Update 2017
Amyloidosis: What to do and how to diagnose: An Update 2017 Jonathan L. Kaufman, MD Associate Professor Hematology & Oncology Winship Cancer Institute of Emory University Amyloidosis Protein Conformation/Deposition
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Multiple Myeloma. Version NCCN.org
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2011 NCCN.org The NCCN Guidelines are a statement of evidence and consensus of the authors regarding their views of currently
More informationMULTIDISCIPLINARY MULTIPLE MYELOMA CARE
MULTIDISCIPLINARY MULTIPLE MYELOMA CARE Regional Lecture Series Leveraging a Multidisciplinary Approach to Multiple Myeloma Care Leveraging a Multidisciplinary Approach to Multiple Myeloma Care Abhinav
More informationCase 1: Mrs. MG. ANCO Hematologic Malignancies Update: Acute leukemias, MDS and myeloma
Partner Logo ANCO Hematologic Malignancies Update: Acute leukemias, MDS and myeloma Tim Campbell Research Fellow UCSF Division of Hematology and Oncology September 12 th, 2015 Case 1: Mrs. MG 65 yo woman
More informationMultiple myeloma. November 24, 2017 at Vientiane, Laos
Multiple myeloma November 24, 2017 at Vientiane, Laos Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi, Mahidol University, Thailand Multiple myeloma
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationHevylite assays de - convoluted. Dr Karthik Ramasamy Oxford University Hospitals
Hevylite assays de - convoluted Dr Karthik Ramasamy Oxford University Hospitals Overview Hevylite assay Introduction Clinical utility of Hevylite 2 Hevylite specifici.es Hevylite specifici.es Hevylite
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationMultiple Myeloma Early Detection, Diagnosis, and Staging
Multiple Myeloma Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be
More informationAnaemias and other Pesky Haematology Questions
Anaemias and other Pesky Haematology Questions 3 main topics How do I work out an anaemia.. That oh too common paraprotein patient. Those mildly raised lymphocyte count GP discussed patient with me over
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationVelcade (bortezomib)
Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 03/09/2004 Current Effective Date: 03/01/2018 POLICY A. INDICATIONS The indications below
More informationAutologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation
() 25, 723 728 Macmillan Publishers Ltd All rights reserved 268 3369/ $15. www.nature.com/bmt Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal
More informationBortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
VOLUME 45 ㆍ NUMBER 3 ㆍ September 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma Se
More informationCenter for Amyloidosis and Acute Phase Proteins, University College London Medical School, UK
Use of plasma cell immunophenotype as prognostic markers in patients with systemic AL amyloidosis Sajitha Sachchithanantham 1*, Anna Baginska 1*, Dorota Rowczenio 1, Shameem A Mahmood 1, Rabya Sayed 1,
More informationHematology Case Conference 8/5/03
Hematology Case Conference 8/5/03 Bone Marrow Case Patient: Emmxxx Lylexxx 74 year old AA female S/P craniotomy for SDH. Pt has Hx of HTN, DM, Crohn s disease, (R) nephrectomy. Bone marrow for abnormal
More informationVelcade (bortezomib)
Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 03/09/2004 Current Effective Date: 05/01/2017 POLICY A. INDICATIONS The indications below
More informationBortezomib (Velcade)
Bortezomib (Velcade) Policy Number: Original Effective Date: MM.04.003 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription Drugs Place(s)
More informationCase #1. Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute
Case #1 Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute Patient History Part I 76 year-old man 1997 diagnosed with MGUS (biclonal) during evaluation of (self-limited) anemia.
More informationUnderstanding the Serum Free Light Chain Assays. Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc.
Understanding the Serum Free Light Chain Assays Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. AL Amyloidosis: abnormality of proteins from Plasma Cells in the Bone Marrow Red
More informationVAD Regimen as Front Line Therapy in Multiple Myeloma
Journal of the Egyptian Nat. Cancer Inst., Vol. 13, No. 4, December: 245-250, 2001 VAD Regimen as Front Line Therapy in Multiple Myeloma FOUAD ABU TALEB, M.D.; AHMAD EL-FAR, M.D.*; WAEL EL-SAWY, M.D.*
More informationBlood and Marrow Transplant Program One Medical Center Dr. Lebanon, NH Phone: (603) Fax: (603)
Blood and Marrow Transplant Program One Medical Center Dr. Lebanon, NH 03756 Phone: (603) 650-4628 Fax: (603) 650-2334 ROUNDTABLE DISCUSSION BEST PRACTICES AT A SMALL TRANSPLANT CENTER Friday, February
More informationMyeloma: Are We on the Brink of a Cure?
Myeloma: Are We on the Brink of a Cure? 1.0 0.9 Survival in Myeloma IFM DFCI; 2015 Proportion Surviving 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 1961-70 2011-14 1991-2000 2001-10 0.0 0 2 4 6 8 10 12 14 16 18 20
More informationOriginal article. Introduction
Original article Annals of Oncology 15: 134 138, 2004 DOI: 10.1093/annonc/mdh026 Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil):
More informationMultiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD
Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD Department of Oncology & Hematology AZ Nikolaas Iridium Kanker Netwerk Introduction Multiple myeloma = Kahler s disease Dr.
More informationSuccessful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy
CASE REPORT Successful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy Naohiro Sekiguchi 1, Naoki Takezako 1, Akihisa Nagata 1, Miyuki Wagatsuma 2, Satoshi Noto 1, Kazuaki
More informationCyclophosphamide, Thalidomide and Dexamethasone- attenuated (CTDa) MMWOS003/01 Indication Oral treatment for multiple myeloma
West of Scotland Cancer Network Chemotherapy Protocol, and - attenuated (CTDa) MMWOS003/01 Indication Oral treatment for multiple myeloma Eligibility criteria Confirmed diagnosis of multiple myeloma First
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationBackground Information
What is Velcade (bortezomib)? Velcade (bortezomib) is a medicine used to treat a blood cancer known as multiple myeloma, and was the first of the treatments in the class of anti-cancer drugs known as proteasome
More informationEBMT2008_22_44:EBMT :26 Pagina 424 CHAPTER 27. HSCT for primary amyloidosis in adults. J. Esteve
EBMT2008_22_44:EBMT2008 6-11-2008 9:26 Pagina 424 * CHAPTER 27 HSCT for primary amyloidosis in adults J. Esteve EBMT2008_22_44:EBMT2008 6-11-2008 9:26 Pagina 425 CHAPTER 27 Amyloidosis in adults 1. Introduction
More informationMM relaps efter min. 3 linie behandlinger.
Inklusionskriterier: Subjects must satisfy the following criteria to be enrolled in the study: 1. Subject is 18 years of age at the time of signing the informed consent form (ICF). 2. Subject must understand
More informationImportance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents Asher A. Chanan-Khan and Sergio Giralt
VOLUME 28 NUMBER 15 MAY 20 2010 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents Asher A. Chanan-Khan
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Multiple Myeloma. NCCN Evidence Blocks. Version November 22, NCCN.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) NCCN Evidence Blocks Version 3.2018 November 22, 2017 NCCN.org Continue Version 3.2018, 11/22/17 National Comprehensive Cancer Network,
More informationThe ABCs of Waldenström s Macroglobulinemia (WM)
The ABCs of Waldenström s Macroglobulinemia (WM) Jeffrey V. Matous MD Colorado Blood Cancer Institute IWMF Ed Forum May 2017 Objectives Describe the roots underneath WM Review incidence, possible risk
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationCONSENSUS DOCUMENT FOR MANAGEMENT OF MUTIPLE MYELOMA
Page 1 of 80 CONSENSUS DOCUMENT FOR MANAGEMENT OF MUTIPLE MYELOMA Prepared as an outcome of ICMR Subcommittee on Multiple Myeloma Page 2 of 80 Disclaimer This consensus statement represents the ICMR s
More informationHodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data
Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Research ID: Event date: / / Visit 100 day 6 months 1 year 2 years
More informationBiology of Blood and Marrow Transplantation 12: (2006) 2006 American Society for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation 12:837-844 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1208-0006$32.00/0 doi:10.1016/j.bbmt.2006.04.006 New Staging Systems
More informationMelphalan, Prednisolone and Thalidomide (MPT) MMWOS001/01 Indication Oral treatment for multiple myeloma
West of Scotland Cancer Network Chemotherapy Protocol Melphalan, and (MPT) MMWOS001/01 Indication Oral treatment for multiple myeloma Eligibility criteria Confirmed diagnosis of multiple myeloma First
More informationSouthern Derbyshire Shared Care Pathology Guidelines. MGUS (Monoclonal Gammopathy of Undetermined Significance)
Southern Derbyshire Shared Care Pathology Guidelines MGUS (Monoclonal Gammopathy of Undetermined Significance) Purpose of guideline This guideline provides information about the risk stratification of
More informationMinimal residual disease. Bruno Paiva University of Navarra, Spain
Minimal residual disease Bruno Paiva University of Navarra, Spain 1st World Congress on Controversies in Multiple Myeloma. Bangkok, Thailand. May 11-13 214 Oprozomib (ONX 912) Phase I/II Autologous bone
More informationMultiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
More informationNeutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt
Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More information